Corcept Names Justin Gunn President of Endocrinology Division
Corcept Therapeutics Inc. announced Justin Gunn will succeed retiring President Sean Maduck to lead the Endocrinology division. This leadership transition reflects the company's continued commercial strengthening and focus on its Cushing's syndrome treatment strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed